Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide-mediated relaxations in arteries of hypertensive rats

Yasuo Kansui, Koji Fujii, Kenichi Goto, Isao Abe, Mitsuo Iida

研究成果: ジャーナルへの寄稿記事

18 引用 (Scopus)

抄録

1. Endothelial cells release endothelium-derived hyperpolarizing factor (EDHF), as well as nitric oxide (NO). It has recently been suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improve NO-mediated endothelial function, partially independently of their cholesterol-lowering effects. It is, however, unclear whether statins improve EDHF-mediated responses. 2. Eight-month-old stroke-prone spontaneously hypertensive rats (SHRSP) were treated with fluvastatin (10 mg/kg per day) for 1 month. Age-matched, normotensive Wistar Kyoto (WKY) rats served as controls. Both EDHF- and NO-mediated relaxations were impaired in SHRSP compared with WKY rats. 3. Fluvastatin treatment did not affect blood pressure and serum total cholesterol. The acetylcholine (ACh)-induced, EDHF-mediated hyperpolarization in mesenteric arteries did not significantly differ between fluvastatin-treated SHRSP and untreated SHRSP and the responses in both groups were significantly smaller compared with those of WKY rats. Endothelium-derived hyperpolarizing factor-mediated relaxations, as assessed by the relaxation to ACh in mesenteric arteries contracted with noradrenaline in the presence of NG-nitro-L- arginine and indomethacin, were virtually absent and similar in both SHRSP groups. In contrast, NO-mediated relaxation, as assessed by the relaxation in response to ACh in rings contracted witli 77 mmol/L KCl, was improved in fluvastatin-treated SHRSP compared with untreated SHRSP (maximum relaxation in control and fluvastatin groups 42.0 ± 5.2 and 61.2 ± 3.8%, respectively; P < 0.05). 4. Hyperpolarization and relaxation in response to levcromakalim, an ATP-sensitive K+ channel opener, were similar between the two SHRSP groups. 5. These findings suggest that fluvasfatin improves NO-mediated relaxation, but not EDHF-mediated hyperpolarization and relaxation, in SHRSP. Thus, the beneficial effects of the statin on endothelial function may be mainly ascribed to an improvement in the NO pathway, but not EDHF.

元の言語英語
ページ(範囲)354-359
ページ数6
ジャーナルClinical and Experimental Pharmacology and Physiology
31
発行部数5-6
DOI
出版物ステータス出版済み - 5 1 2004

Fingerprint

fluvastatin
Endothelium
Nitric Oxide
Arteries
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Inbred WKY Rats
Acetylcholine
Mesenteric Arteries
Cholesterol
Cromakalim
Nitroarginine
Inbred SHR Rats
Indomethacin
Norepinephrine
Oxidoreductases

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology
  • Physiology (medical)

これを引用

Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide-mediated relaxations in arteries of hypertensive rats. / Kansui, Yasuo; Fujii, Koji; Goto, Kenichi; Abe, Isao; Iida, Mitsuo.

:: Clinical and Experimental Pharmacology and Physiology, 巻 31, 番号 5-6, 01.05.2004, p. 354-359.

研究成果: ジャーナルへの寄稿記事

@article{7ffbe64e66994039ad9f6b34df6b8d2c,
title = "Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide-mediated relaxations in arteries of hypertensive rats",
abstract = "1. Endothelial cells release endothelium-derived hyperpolarizing factor (EDHF), as well as nitric oxide (NO). It has recently been suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improve NO-mediated endothelial function, partially independently of their cholesterol-lowering effects. It is, however, unclear whether statins improve EDHF-mediated responses. 2. Eight-month-old stroke-prone spontaneously hypertensive rats (SHRSP) were treated with fluvastatin (10 mg/kg per day) for 1 month. Age-matched, normotensive Wistar Kyoto (WKY) rats served as controls. Both EDHF- and NO-mediated relaxations were impaired in SHRSP compared with WKY rats. 3. Fluvastatin treatment did not affect blood pressure and serum total cholesterol. The acetylcholine (ACh)-induced, EDHF-mediated hyperpolarization in mesenteric arteries did not significantly differ between fluvastatin-treated SHRSP and untreated SHRSP and the responses in both groups were significantly smaller compared with those of WKY rats. Endothelium-derived hyperpolarizing factor-mediated relaxations, as assessed by the relaxation to ACh in mesenteric arteries contracted with noradrenaline in the presence of NG-nitro-L- arginine and indomethacin, were virtually absent and similar in both SHRSP groups. In contrast, NO-mediated relaxation, as assessed by the relaxation in response to ACh in rings contracted witli 77 mmol/L KCl, was improved in fluvastatin-treated SHRSP compared with untreated SHRSP (maximum relaxation in control and fluvastatin groups 42.0 ± 5.2 and 61.2 ± 3.8{\%}, respectively; P < 0.05). 4. Hyperpolarization and relaxation in response to levcromakalim, an ATP-sensitive K+ channel opener, were similar between the two SHRSP groups. 5. These findings suggest that fluvasfatin improves NO-mediated relaxation, but not EDHF-mediated hyperpolarization and relaxation, in SHRSP. Thus, the beneficial effects of the statin on endothelial function may be mainly ascribed to an improvement in the NO pathway, but not EDHF.",
author = "Yasuo Kansui and Koji Fujii and Kenichi Goto and Isao Abe and Mitsuo Iida",
year = "2004",
month = "5",
day = "1",
doi = "10.1111/j.1440-1681.2004.04011.x",
language = "English",
volume = "31",
pages = "354--359",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "5-6",

}

TY - JOUR

T1 - Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide-mediated relaxations in arteries of hypertensive rats

AU - Kansui, Yasuo

AU - Fujii, Koji

AU - Goto, Kenichi

AU - Abe, Isao

AU - Iida, Mitsuo

PY - 2004/5/1

Y1 - 2004/5/1

N2 - 1. Endothelial cells release endothelium-derived hyperpolarizing factor (EDHF), as well as nitric oxide (NO). It has recently been suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improve NO-mediated endothelial function, partially independently of their cholesterol-lowering effects. It is, however, unclear whether statins improve EDHF-mediated responses. 2. Eight-month-old stroke-prone spontaneously hypertensive rats (SHRSP) were treated with fluvastatin (10 mg/kg per day) for 1 month. Age-matched, normotensive Wistar Kyoto (WKY) rats served as controls. Both EDHF- and NO-mediated relaxations were impaired in SHRSP compared with WKY rats. 3. Fluvastatin treatment did not affect blood pressure and serum total cholesterol. The acetylcholine (ACh)-induced, EDHF-mediated hyperpolarization in mesenteric arteries did not significantly differ between fluvastatin-treated SHRSP and untreated SHRSP and the responses in both groups were significantly smaller compared with those of WKY rats. Endothelium-derived hyperpolarizing factor-mediated relaxations, as assessed by the relaxation to ACh in mesenteric arteries contracted with noradrenaline in the presence of NG-nitro-L- arginine and indomethacin, were virtually absent and similar in both SHRSP groups. In contrast, NO-mediated relaxation, as assessed by the relaxation in response to ACh in rings contracted witli 77 mmol/L KCl, was improved in fluvastatin-treated SHRSP compared with untreated SHRSP (maximum relaxation in control and fluvastatin groups 42.0 ± 5.2 and 61.2 ± 3.8%, respectively; P < 0.05). 4. Hyperpolarization and relaxation in response to levcromakalim, an ATP-sensitive K+ channel opener, were similar between the two SHRSP groups. 5. These findings suggest that fluvasfatin improves NO-mediated relaxation, but not EDHF-mediated hyperpolarization and relaxation, in SHRSP. Thus, the beneficial effects of the statin on endothelial function may be mainly ascribed to an improvement in the NO pathway, but not EDHF.

AB - 1. Endothelial cells release endothelium-derived hyperpolarizing factor (EDHF), as well as nitric oxide (NO). It has recently been suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improve NO-mediated endothelial function, partially independently of their cholesterol-lowering effects. It is, however, unclear whether statins improve EDHF-mediated responses. 2. Eight-month-old stroke-prone spontaneously hypertensive rats (SHRSP) were treated with fluvastatin (10 mg/kg per day) for 1 month. Age-matched, normotensive Wistar Kyoto (WKY) rats served as controls. Both EDHF- and NO-mediated relaxations were impaired in SHRSP compared with WKY rats. 3. Fluvastatin treatment did not affect blood pressure and serum total cholesterol. The acetylcholine (ACh)-induced, EDHF-mediated hyperpolarization in mesenteric arteries did not significantly differ between fluvastatin-treated SHRSP and untreated SHRSP and the responses in both groups were significantly smaller compared with those of WKY rats. Endothelium-derived hyperpolarizing factor-mediated relaxations, as assessed by the relaxation to ACh in mesenteric arteries contracted with noradrenaline in the presence of NG-nitro-L- arginine and indomethacin, were virtually absent and similar in both SHRSP groups. In contrast, NO-mediated relaxation, as assessed by the relaxation in response to ACh in rings contracted witli 77 mmol/L KCl, was improved in fluvastatin-treated SHRSP compared with untreated SHRSP (maximum relaxation in control and fluvastatin groups 42.0 ± 5.2 and 61.2 ± 3.8%, respectively; P < 0.05). 4. Hyperpolarization and relaxation in response to levcromakalim, an ATP-sensitive K+ channel opener, were similar between the two SHRSP groups. 5. These findings suggest that fluvasfatin improves NO-mediated relaxation, but not EDHF-mediated hyperpolarization and relaxation, in SHRSP. Thus, the beneficial effects of the statin on endothelial function may be mainly ascribed to an improvement in the NO pathway, but not EDHF.

UR - http://www.scopus.com/inward/record.url?scp=3042524990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042524990&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1681.2004.04011.x

DO - 10.1111/j.1440-1681.2004.04011.x

M3 - Article

C2 - 15191411

AN - SCOPUS:3042524990

VL - 31

SP - 354

EP - 359

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 5-6

ER -